ATE552274T1 - Mhc-oligomer und verfahren zu dessen herstellung - Google Patents

Mhc-oligomer und verfahren zu dessen herstellung

Info

Publication number
ATE552274T1
ATE552274T1 AT06703945T AT06703945T ATE552274T1 AT E552274 T1 ATE552274 T1 AT E552274T1 AT 06703945 T AT06703945 T AT 06703945T AT 06703945 T AT06703945 T AT 06703945T AT E552274 T1 ATE552274 T1 AT E552274T1
Authority
AT
Austria
Prior art keywords
mhc
peptide
production
binding groove
mhc oligomer
Prior art date
Application number
AT06703945T
Other languages
English (en)
Inventor
Nikolai Schwabe
Original Assignee
Proimmune Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Proimmune Ltd filed Critical Proimmune Ltd
Application granted granted Critical
Publication of ATE552274T1 publication Critical patent/ATE552274T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/34—Extraction; Separation; Purification by filtration, ultrafiltration or reverse osmosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Water Supply & Treatment (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Materials For Medical Uses (AREA)
  • Polyoxymethylene Polymers And Polymers With Carbon-To-Carbon Bonds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AT06703945T 2005-02-04 2006-02-01 Mhc-oligomer und verfahren zu dessen herstellung ATE552274T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0502333A GB2422834B8 (en) 2005-02-04 2005-02-04 MHC oligomer and method of making the same
PCT/GB2006/000320 WO2006082387A1 (en) 2005-02-04 2006-02-01 Mhc oligomer and method of making the same

Publications (1)

Publication Number Publication Date
ATE552274T1 true ATE552274T1 (de) 2012-04-15

Family

ID=34355794

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06703945T ATE552274T1 (de) 2005-02-04 2006-02-01 Mhc-oligomer und verfahren zu dessen herstellung

Country Status (10)

Country Link
US (2) US20080207485A1 (de)
EP (1) EP1844072B1 (de)
JP (1) JP2008529994A (de)
CN (1) CN101111520A (de)
AT (1) ATE552274T1 (de)
AU (1) AU2006210705A1 (de)
CA (1) CA2596953A1 (de)
DK (1) DK1844072T3 (de)
GB (1) GB2422834B8 (de)
WO (1) WO2006082387A1 (de)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2440529B (en) * 2006-08-03 2009-05-13 Proimmune Ltd MHC Oligomer, Components Therof, And Methods Of Making The Same
EP2155782A2 (de) 2007-03-26 2010-02-24 Dako Denmark A/S Mhc-peptid-komplexe und anwendungen davon bei infektionskrankheiten
EP2167537A2 (de) 2007-07-03 2010-03-31 Dako Denmark A/S Zusammengestellte verfahren für die analyse und sortierung von proben
US8431394B2 (en) * 2007-07-13 2013-04-30 INSERM (Institut National de la Santé et de la Recherche Médicale) Antibody or fragment thereof recognizing Avitag™ and uses thereof
US10611818B2 (en) 2007-09-27 2020-04-07 Agilent Technologies, Inc. MHC multimers in tuberculosis diagnostics, vaccine and therapeutics
EA019836B1 (ru) 2007-11-02 2014-06-30 Те Джонс Хопкинс Юниверсити Композиции многотипных пептидов hpv и способы лечения или предотвращения папилломавирусной инфекции у человека
DK2254592T3 (da) 2008-02-28 2019-09-09 Dako Denmark As MHC-multimerer til Borrelia-diagnostik og sygdom
WO2010009735A2 (en) 2008-07-23 2010-01-28 Dako Denmark A/S Combinatorial analysis and repair
GB0817244D0 (en) 2008-09-20 2008-10-29 Univ Cardiff Use of a protein kinase inhibitor to detect immune cells, such as T cells
WO2010037397A1 (en) * 2008-10-01 2010-04-08 Dako Denmark A/S Mhc multimers in cmv immune monitoring
WO2010037402A1 (en) 2008-10-02 2010-04-08 Dako Denmark A/S Molecular vaccines for infectious disease
US11992518B2 (en) 2008-10-02 2024-05-28 Agilent Technologies, Inc. Molecular vaccines for infectious disease
CN101747412A (zh) * 2009-12-30 2010-06-23 江苏诺泰制药技术有限公司 一种依替非巴肽的合成制备工艺
WO2011147894A1 (en) * 2010-05-25 2011-12-01 Forschungsverbund Berlin E.V. Chimeric mhc class ii proteinpeptide
CA2951325C (en) * 2014-06-06 2023-09-12 Herlev Hospital Determining antigen recognition through barcoding of mhc multimers
WO2015188839A2 (en) 2014-06-13 2015-12-17 Immudex Aps General detection and isolation of specific cells by binding of labeled molecules
US10294454B2 (en) 2016-08-24 2019-05-21 General Electric Company Methods and kits for cell activation
WO2020127222A2 (en) 2018-12-17 2020-06-25 Immudex Aps Panel comprising borrelia mhc multimers
CN115776987A (zh) * 2020-03-31 2023-03-10 瑞佩尔托利免疫医药股份有限公司 可条码化可交换肽-mhc多聚体文库

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993010220A1 (en) 1991-11-19 1993-05-27 Anergen, Inc. Soluble mhc molecules and their uses
US5763585A (en) * 1993-10-13 1998-06-09 Anergen, Inc. Method of making MHC-peptide complexes using metal chelate affinity chromatography
CA2140591A1 (en) * 1994-01-20 1995-07-21 Josef Endl Antigen-specific, activated t lymphocytes, detection and use
US5635363A (en) 1995-02-28 1997-06-03 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for the detection, quantitation and purification of antigen-specific T cells
US5869270A (en) * 1996-01-31 1999-02-09 Sunol Molecular Corporation Single chain MHC complexes and uses thereof
JP2000516808A (ja) * 1996-08-05 2000-12-19 プレジデント アンド フェローズ オブ ハーバード カレッジ Ｍｈｃ結合ペプチドオリゴマーおよび使用方法
CA2406378A1 (en) * 2000-04-12 2001-10-25 University Of Rochester Targeted vaccine delivery systems
AU2001271273A1 (en) * 2000-05-24 2001-12-03 Ludwig Institute For Cancer Research Multicomponent conjugates which bind to target molecules and stimulate cell lysis
GB2392158B (en) * 2002-08-21 2005-02-16 Proimmune Ltd Chimeric MHC protein and oligomer thereof

Also Published As

Publication number Publication date
EP1844072B1 (de) 2012-04-04
GB2422834B8 (en) 2007-01-04
JP2008529994A (ja) 2008-08-07
GB2422834B (en) 2007-01-03
US20080207485A1 (en) 2008-08-28
AU2006210705A1 (en) 2006-08-10
WO2006082387A1 (en) 2006-08-10
GB2422834A (en) 2006-08-09
EP1844072A1 (de) 2007-10-17
CA2596953A1 (en) 2006-08-10
DK1844072T3 (da) 2012-07-23
GB0502333D0 (en) 2005-03-16
CN101111520A (zh) 2008-01-23
US20120121641A1 (en) 2012-05-17

Similar Documents

Publication Publication Date Title
GB2422834B8 (en) MHC oligomer and method of making the same
ATE497984T1 (de) Dimercaptanterminierte polythioetherpolymere und verfahren zu ihrer herstellung und verwendung
DE602004027978D1 (de) Verbundwerkstoff und Verfahren zu dessen Herstellung
EP1759040A4 (de) Polymere strukturen und verfahren zu deren herstellung
NO20054079D0 (no) Hydrokarbongassprosess.
AT500656A3 (de) Mehrteilige baugruppe, verfahren und schweissanlage zur herstellung der baugruppe
DE602005020467D1 (de) Dielektrische luneberglinse und verfahren zu ihrer herstellung
WO2004106380A3 (en) Human-anti-human cd3 binding molecules
DE602006014067D1 (de) Verfahren und System zum Herunterladen von Daten in mobilen Endgeräten und zur Implementierung von Datensammlung zwischen mobilen Endgeräten
ATE419260T1 (de) C-aryl-glucosid-sglt2-inhibitoren und verfahren zu ihrer herstellung
DE502006000218D1 (de) Verfahren zur Herstellung von SiOC-verknüpften, linearen Polydialkylsiloxan-Polyoxyalkylen-Blockcopolymeren
IL184524A0 (en) Substituted pyrazolo-pyridines, compositions containing them, method for the production thereof, and their use
EP2426141A3 (de) Verfahren zur Vorbeugung oder Behandlung einer M-tuberculosis-Infektion
DE60332953D1 (de) Gleichmässiges faservlies und verfahren zu dessen herstellung
ATE526272T1 (de) Riemen für eine aufzuganlage, herstellungsverfahren für einen solchen riemen und aufzuganlage mit einem solchen riemen
NO20064454L (no) Matstang og fremgangsmåte for fremstilling derav.
ATA5982004A (de) Hydraulisches bindemittel sowie verfahren zu dessen herstellung
EP1906468A4 (de) Batteriedose und verfahren zu ihrer herstellung
ATE535510T1 (de) Benzylamine, verfahren zu ihrer herstellung und ihre verwendung als entzündungshemmende mittel
DE602004008991D1 (de) Umlenkbeschlag und verfahren zu dessen herstellung
DE602004029319D1 (de) Verbindung mit phoshorylcholingruppe, dessen polymer und verfahren zu dessen herstellung
DE60223136D1 (de) Mikroelektromechanisches Bauelement, insbesondere Mikroaktor für Festplatteneinheiten, und Verfahren zu dessen Herstellung
DE602005026176D1 (de) Rollenlose spule und verfahren zu ihrer herstellung
ATA3752003A (de) Verbundwerkstoff und verfahren zu dessen herstellung
DE502005000428D1 (de) Verfahren zur Herstellung von 1,2-Diaminocyclohexan-Platin(II)-Komplexen